WO2006078245A1 - Simulated vernix compositions for skin cleansing and other applications - Google Patents
Simulated vernix compositions for skin cleansing and other applications Download PDFInfo
- Publication number
- WO2006078245A1 WO2006078245A1 PCT/US2005/001839 US2005001839W WO2006078245A1 WO 2006078245 A1 WO2006078245 A1 WO 2006078245A1 US 2005001839 W US2005001839 W US 2005001839W WO 2006078245 A1 WO2006078245 A1 WO 2006078245A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- water
- vernix
- cholesterol
- lanolin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 207
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 214
- 150000002632 lipids Chemical class 0.000 claims abstract description 52
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 27
- 239000002245 particle Substances 0.000 claims abstract description 22
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims abstract description 19
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims abstract description 19
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940031439 squalene Drugs 0.000 claims abstract description 19
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 17
- 239000002480 mineral oil Substances 0.000 claims abstract description 17
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 17
- 239000004264 Petrolatum Substances 0.000 claims abstract description 10
- 229940066842 petrolatum Drugs 0.000 claims abstract description 10
- 235000019271 petrolatum Nutrition 0.000 claims abstract description 10
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 claims abstract description 9
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims abstract description 9
- 239000003921 oil Substances 0.000 claims abstract description 9
- 235000021588 free fatty acids Nutrition 0.000 claims abstract description 6
- 229940106189 ceramide Drugs 0.000 claims abstract description 5
- 239000004164 Wax ester Substances 0.000 claims abstract description 3
- 150000001840 cholesterol esters Chemical class 0.000 claims abstract description 3
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 3
- 150000003727 wax diesters Chemical class 0.000 claims abstract description 3
- 235000019386 wax ester Nutrition 0.000 claims abstract description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- 239000004166 Lanolin Substances 0.000 claims description 24
- 229940039717 lanolin Drugs 0.000 claims description 24
- 235000019388 lanolin Nutrition 0.000 claims description 24
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 20
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 claims description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 18
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 18
- 229960005078 sorbitan sesquioleate Drugs 0.000 claims description 18
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 18
- 230000005540 biological transmission Effects 0.000 claims description 16
- 229940031709 peg-30-dipolyhydroxystearate Drugs 0.000 claims description 16
- 235000013871 bee wax Nutrition 0.000 claims description 14
- 239000012166 beeswax Substances 0.000 claims description 14
- 229940085262 cetyl dimethicone Drugs 0.000 claims description 14
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 13
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 12
- 239000001993 wax Substances 0.000 claims description 11
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 10
- 229960002216 methylparaben Drugs 0.000 claims description 10
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 9
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 claims description 9
- 229940107161 cholesterol Drugs 0.000 claims description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 9
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 9
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 9
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 9
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 9
- 229960003415 propylparaben Drugs 0.000 claims description 9
- 229940100518 polyglyceryl-4 isostearate Drugs 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 6
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 claims description 5
- 229940100463 hexyl laurate Drugs 0.000 claims description 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 3
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- 150000002430 hydrocarbons Chemical class 0.000 claims description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims description 2
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical group O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000007957 coemulsifier Substances 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- 229940048845 polyglyceryl-3 diisostearate Drugs 0.000 claims description 2
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000011159 matrix material Substances 0.000 abstract description 10
- 230000036571 hydration Effects 0.000 abstract description 6
- 238000006703 hydration reaction Methods 0.000 abstract description 6
- 230000002209 hydrophobic effect Effects 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 abstract description 4
- 150000001783 ceramides Chemical class 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 62
- 239000010408 film Substances 0.000 description 23
- 230000032258 transport Effects 0.000 description 19
- 239000004094 surface-active agent Substances 0.000 description 12
- 238000004364 calculation method Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 239000002689 soil Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- -1 polyoxyethylene Polymers 0.000 description 8
- 239000003599 detergent Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 235000020778 linoleic acid Nutrition 0.000 description 6
- 229960004232 linoleic acid Drugs 0.000 description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 6
- 239000000344 soap Substances 0.000 description 6
- 210000000245 forearm Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 230000003655 tactile properties Effects 0.000 description 5
- 229930182558 Sterol Natural products 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940003587 aquaphor Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 239000007762 w/o emulsion Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 239000000592 Artificial Cell Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000005081 epithelial layer Anatomy 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- RNNBHZYEKNHLKT-UHFFFAOYSA-N isopropylmethylpyrazolyl dimethylcarbamate Chemical compound CC(C)N1N=C(C)C=C1OC(=O)N(C)C RNNBHZYEKNHLKT-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003397 biobrane Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000003738 black carbon Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 229940073551 distearyldimonium chloride Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229920006298 saran Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/927—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of insects, e.g. shellac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Definitions
- One embodiment is a synthetic vernix composition having a continuous lipid phase where the lipids are substantially physiologic lipids, and a water phase of simulated cells dispersed in the lipid phase, the water phase capable of retaining greater than about 65% w/w water of the total composition, with water vapor transport through the composition that ranges between about 85% of water vapor transport through a substantially highly permeable composition and about 5% of water vapor transport through a substantially highly occlusive composition, and a rate of evaporative water loss from the composition from about -38% water in composition/hr to 0% water in composition/hr from 0 h to 0.5 hr, that is, up to about 38% water loss within the first half-hour, and from about -8% water in composition/hr to 0% water in composition/hr from 0.5 hr to 3 hr, that is, up to about 8% water loss after the first half-hour and for the next two and one-half hours.
- Another embodiment is a synthetic vernix composition having a lipid phase and a water phase, with the lipid phase having at least one emulsifying agent to form hydratable water-in-oil emulsified particles.
- the emulsifying agent has a hydrophile-lipophile balance (HLB) value such that the emulsifying agent does not substantially dissolve in the water phase.
- HLB hydrophile-lipophile balance
- the HLB value may range between about 3 to about 6.
- the synthetic vernix composition comprises hydratable water-in-oil emulsified particles having a lipid phase comprising lanolin, squalene, linoleic acid, cholesterol, ceramide III, wax, capric/caprilic triglyceride, cholesterol sulfate; PEG30 dipolyhydroxystearate and sorbitan sesquioleate emulsifying agents; and a water phase containing methylparaben and/or propylparaben, magnesium sulfate, glycerin, and water in concentrations sufficient to provide water vapor transport, evaporative water loss, tactile and rheological properties simulating native vernix.
- a lipid phase comprising lanolin, squalene, linoleic acid, cholesterol, ceramide III, wax, capric/caprilic triglyceride, cholesterol sulfate; PEG30 dipolyhydroxystearate and sorbitan sesquioleate emuls
- the synthetic vernix composition comprises hydratable water-in-oil emulsified particles having a lipid phase comprising lanolin, stearyl alcohol, wax, mineral oil, and petrolatum; cetyl dimethicone copolyol and Abil WE09 (polyglyceryl-4-isostearate and cetyl dimethicone copolyol and hexyl laurate) emulsifying agents, and water.
- Another embodiment is a method of using synthetic vernix to remove soil from a skin surface. The composition is applied to the soiled surface, then is removed along with the soiling material.
- the method may be used on a premature or full term infant, a child, an adult, a geriatric patient, and the composition may be used on an intact or compromised surface, such as a wound or ulcer.
- the method may be used with a synthetic vernix composition that also contains a soap and/or surfactant.
- Another embodiment is a method for fully or partially cleansing a baby (full term or premature) immediately after birth with a composition containing synthetic vernix to remove amniotic fluid, endogenous vernix, meconium, blood and other fluids, upon removing the composition.
- Another embodiment is a method of cleaning a soiled skin surface by applying a composition consisting essentially of synthetic vernix under conditions to emulsify the soiling material in the vernix, and then removing the vernix and emulsified soiling material.
- the amount of synthetic vernix may be up to about 16 mg/cm 2 .
- Another embodiment is a method of cleansing skin by applying a nontoxic film having a thickness up to about 16 mg/cm 2 and consisting essentially of synthetic vernix to a layer of epithelial cells to provide a skin cleansing effect.
- the film may be applied either directly or indirectly to the surface; for example, it may be applied to a wash cloth, a wipe, a bandage, a pad, etc.
- Another embodiment is a method of cleansing an epithelial layer by applying a non-toxic film having a thickness of up to about 16 mg/cm 2 and consisting essentially of synthetic vernix to the epithelial layer, and then removing the film from the cleansed tissue.
- Another embodiment is a method to protect a skin surface of an individual who is, or may be, susceptible to commercially available cleansing products (e.g., one allergic to some commercial soaps or cleansers).
- a composition consisting essentially of synthetic vernix is applied to a skin surface of this individual in an amount up to 16 mg/cm 2 before exposing the skin surface to the product.
- Another embodiment is a method to remove a soiling material from a skin surface by providing synthetic vernix and at least one soap or surfactant to the soiled surface under conditions resulting in flocculation and detachment of the soil from the surface.
- FIG. 1 schematically illustrates simulated cells dispersed in a lipid matrix.
- FIGS. 2A, 2B, and 2C show evaporative water loss profiles of embodiments of synthetic vernix.
- FIGS. 3A, 3B, and 3C are digital images of volar forearm skin, either unsoiled (FIGS. 3A1 and 3A2, after application of a soiling material (FIGS. 3B1 and 3B2), or after application of a synthetic vernix (FIGS. 3C1 and 3C2).
- FIGS. 4A, 4B, 4C, 4D, 4E, and 4F are histograms quantitating the amount of soiling material on the skin surface of unsoiled (baseline), soiled, and cleansed skin treated with water (FIG. 4A), Aquaphor (FIG. 4B), commercial cleansers (FIGS. 4C, 4D), synthetic vernix (FlG. 4E), and native vernix (FIG. 4F).
- FIG. 5 is a plot of differences in L-scale scores before and after cleansing with various treatments.
- FIGS. 6A1-6A6, 6B1-6B6, and 6C are representative digital images converted to black and white counterpart images and graphical results of skin treated with synthetic vernix and other cleansing agents. Detailed Description
- a nontoxic simulated vernix composition also referred to herein as synthetic vernix, contains a component of simulated cells and a component of at least one lipid.
- the inventive composition simulates the hydration, barrier, rheological, tactile, and other properties of native vernix. With respect to its hydration properties, native vernix provides both hydrophilic properties from the water associated with its cellular component, and hydrophobic properties from its lipid component.
- the inventive composition simulates hydrophilic properties of native vernix by hydrated emulsified water droplets, referred to herein as emulsified particles, that have the capability to retain, in a hydrated state, at least 65% ⁇ water in the composition in their internal (water) phase.
- the inventive composition simulates hydrophobic properties of native vernix by a matrix of one or more lipids that are present in native vernix, in which the simulated cells are dispersed.
- the lipids are substantially physiologic.
- the inventive composition thus retains or is capable of retaining water at a concentration that simulates native vernix, and transports water vapor at a rate that simulates native vernix.
- Native vernix encompasses vernix as it is obtained from a newborn, as well as vernix obtained from a newborn that has been rendered tractable, as described in U.S. Patent Nos. 5,989,577; 6,113,932; 6,333,041; and U.S. Patent application Serial Nos. 09/850,844 (now U.S. Patent No. 6,562,358); 10/241 ,184; 60/377,430 and 60/439,966; and PCT application Serial No. PCT/US03/13612, now U.S. Patent application Serial No. 10/512,933, each of which is expressly incorporated by reference herein in its entirety.
- the cell component of native vernix is replaced by hydratable emulsified particles that perform the hydration functions of cells; these structures may be termed "simulated cells” or “synthetic cells”.
- the "cellular" component also referred to herein as simulated cells, hydrates a surface to which the inventive composition is applied. It does this by slowly releasing water and by transporting water vapor, as cells do in native vernix.
- the simulated cells in small particle form are mixed into a lipid matrix.
- the lipid matrix contains at least one commercially available lipid that is present in native vernix. Any or all of the following lipids may be used, each of which is found in native vernix, and each of which is available commercially (for > example, Sigma, St.
- the composition of the lipid phase may be varied to provide the desired spreading characteristics and viscosity for the final composition. For example, a relatively higher wax content will produce a less spreadable, more viscous composition than a relatively lower wax content; a relatively higher free fatty acid and/or triglyceride content will produce a more easily spreadable, less viscous composition than a relatively lower free fatty acid and/or triglyceride content.
- Phase stable water-in-oil emulsions in small particle form in a lipid matrix provided compositions that simulated native vernix. This is shown schematically in FIG. 1 where water droplets 10 exist in a lipid matrix 20, the water droplets 10 packaged in particles 30 as emulsions.
- the synthetic vernix compositions substantially duplicated properties of native vernix.
- the emulsified particles performed the function of the biological cells in native vernix with respect to regulating water transport, permeability, barrier, water- loss, and other properties relating to water behavior.
- the emulsions effectively allowed the water to exist in droplets, i.e., packaged as droplets.
- Emulsifying agents or emulsifiers are generally considered to be surface active agents or surfactants. While the term surfactant may refer to cleaning ability, in the case of the inventive compositions hydrophile-lipophile balance (HLB) is used to describe the nature of the emulsifier.
- HLB hydrophile-lipophile balance
- the HLB of the emulsifier is selected so as to keep the water retained within the particular matrix of the formulation. If the HLB is too high, the emulsifier will dissolve in the water and therefore not keep the water as droplets within the lipid matrix.
- HLB is a property represented on an arbitrary scale of 0-20 for non- ionic surfactants, withhigher numbers indicating the most hydrophilic surface active agents, and lower numbers indicating the most hydrophobic surface active agents.
- the HLB of a nonionic surfactant is the approximate weight of ethylene oxide in the surfactant divided by 5.
- polyoxyethylene derivatives of Spans Tweens
- Spans sorbitan esters
- the HLB of oleic acid is 1 ; the HLB of glyceryl monostearate (Span 80) is 3.8; the HLB of sorbitan monooleate (Span 20) is 4.3; the HLB of triethanolamine oleate is 12.0; the HLB of polyoxyethylene sorbitan is 15; the HLB of monooleate (Tween 80) polyoxyethylene sorbitan is 16.7; the HLB of monolaurate (Tween 20) sodium oleate is 18.0; the HLB of sodium lauryl sulfate is 40.
- the HLB values of the emulsifying agents ranged from lower than 4 to about 6. In one embodiment, the HLB ranged from 3.8 to 6.0. In one embodiment, the HLB was about 3.8.
- These emulsifying agents provided a high internal phase (i.e., water phase) system, containing water as greater than about 65% w/w of its total volume, and yielded a water loss profile simulating native vernix.
- the emulsifying agents were polyhydroxy hydrocarbons. In another embodiment the emulsifying agents were the non-
- ionic PEG-7 hydrogenated castor oil (Cremophore WO7®) (4% w/w ), or polyglyceryl-4 isostearate and cetyl dimethicone copolyol and hexyl laurate (Abil WE09) (5% w/w ).
- the emulsifying agents were cremophore WO7 (0.8% w/w ) and cetyl dimethicone copolyol (2% w/w ).
- the emulsifying agents were cetyl dimethicone copolyol (1 % w/w ) and Abil WE 09 (2% w/w ).
- the emulsifying agent was Abil WE 09 (2% w/w ).
- the emulsifying agents were PEG-30 dipolyhydroxystearate (Arlacel P 135®, Uniqema, USA) (about 1.5% w/w ) and sorbitan sesquioleate (Uniqema) (about 0.5% w/w ).
- the emulsifying agent is polyglyceryl-3-diisostearate (Unichema, Gouda, NL) and cetyl dimethicone copolyol.
- the emulsifying agent is polyglyceryl-3-oleate (Danisco AJS, Copenhagen DK).
- the emulsifying agent is polyglyceryl-4-isostearate (about 2.5% w/w to about 4% w/w ) (ISOLAN Gl 34, Goldschmidt, Mannheim, DE).
- emulsifying agent(s) is/are used with methyl glucose isostearate (about 2% w/w to about 5% w/w ) (ISOLAN IS, Goldschmidt) as a co-emulsifier.
- the emulsifying agents were selected to minimize irritancy when the inventive composition was applied to a skin surface.
- "low irritancy" materials cause little or no irritation in skin irritancy testing and among individuals with irritated skin, reactive skin conditions, or with susceptibility to skin irritation. Therefore, skin care product ingredients can be classified according to their effects on skin in standard testing.
- One irritancy test is the Human Patch Test. The materials to be evaluated are applied under an occlusive patch and left on the skin for up to 24 hours. Following application, the skin condition is evaluated by standard methods, such as dryness and erythema scoring using visual grading scales or instrumental measurement of skin barrier integrity and function.
- Low irritancy materials have relatively low Patch Test scores, e.g., 0.2-0.5 on a 0-4 scale, and/or cause substantially no irritation in a large population of healthy subjects.
- emulsifiers with low irritancy were selected over emulsifiers that yielded a stable product but that had the potential to cause low levels of irritation in irritated skin populations.
- Physiologic lipids that are found in native vernix were incorporated in the formulation to constitute the lipid matrix. These included cholesterol and squalene (both from Sigma Aldrich, St. Louis, MO), ceramide III (Cosmoferm, NL), cholesterol sulfate (Acros Organics, Leicestershire, UK), linoleic acid (Henkel Corporation-Emery Group, Cincinnati OH), lanolin (Amerchol, Midland Ml), triglyceride (e.g., capric caprilic triglyceride) (Henkel), and wax (e.g. beeswax USP). Other physiologically acceptable lipids, such as Petrolatum® (CVS, Woonsocket, Rl) and/or mineral oil, may be included in some formulations.
- Petrolatum® such as Petrolatum® (CVS, Woonsocket, Rl) and/or mineral oil
- the inventive simulated vernix composition retained, or was capable of retaining, greater than about 65% water of the total composition by weight in its internal (water) phase. Additional components may assist in maintaining the emulsion, providing hydration, etc.
- the water phase may contain electrolytes.
- the water phase contained magnesium sulfate (The PQ Corp, Berwyn, PA) which binds water, assists in water release properties of the synthetic cell, and stabilizes the water-in-oil emulsion.
- the water phase contained glycerin (Cognis, Cincinnati, OH). Glycerin has a high affinity for water and therefore assists with slow release of the water; it also binds water to the skin surface.
- the water phase contained a preservative such as methylparaben and/or propylparaben (Chatham ISP Sutton Laboratories, Wayne NJ).
- a preservative such as methylparaben and/or propylparaben (Chatham ISP Sutton Laboratories, Wayne NJ).
- the inventive composition is applied to a physiologically acceptable support structure in a liquid state to form a film. It is presented as .droplets which coalesce to form a film upon encountering the support.
- a film is defined herein as an interfacial surface covering, in either a liquid or a solid state, with temperature-dependant properties. Film-forming techniques include but are not limited to spraying, extruding, blowing, pouring, evaporating, coating and painting.
- a preformed film of the inventive composition is applied to a physiologically acceptable support.
- the physiologically acceptable support is one that can withstand sterilization, preferably by standard sterilization techniques known to one skilled in the art such as exposing to gamma radiation, autoclaving, and so on.
- the support is not limited to a particular composition or configuration and, depending upon its use, may or may not be sterilized and may take various forms.
- the film is used to enhance skin cell maturation and may be applied to structures such as filters, membranes, beads, particles, and so on.
- the support structure is not limited to a particular state of matter and may be a solid, a semi-solid, a gel and so on.
- the support consists of a nylon monofilament interpositional surfacing material such as N-terface® pads (Winfield Laboratories, Inc., Richardson TX), Biobrane II® (Sterling Drug Inc., New York NY) or circular nylon filters of suitable porosity (Micron Separations Inc., Westboro MA).
- nylon monofilament interpositional surfacing material such as N-terface® pads (Winfield Laboratories, Inc., Richardson TX), Biobrane II® (Sterling Drug Inc., New York NY) or circular nylon filters of suitable porosity (Micron Separations Inc., Westboro MA).
- Other support materials may also be used to practice the invention.
- the film of the inventive composition is used to promote wound healing and/or tissue repair. It may be applied to various materials for placement either in direct contact or indirect contact with an intact or compromised skin site requiring treatment, such as a wound, an abrasion, an ulcer, a burned area, a site of infection or irritation, a wart, etc.
- the support may be permeable to physical and/or chemical agents, and may take a variety of forms, depending upon its purpose and the extent of the area requiring dressing or treatment.
- the film may be applied to various synthetics such as thermoplastic films, blown films and breathable films, and various natural and synthetic fabric compositions such as woven, non-woven, spun, and stitched fabrics.
- the invention may be used in a variety of products, examples of which include wound dressings and coverings such as bandages, tapes, gauze, adhesive products applied for a short or long term to the skin, ostomy care products, hospital pads such as incontinent pads, absorbent pads, and examination pads, disposable and cloth diapers, and feminine hygiene products such as intralabial devices.
- the inventive composition may be used therapeutically to promote skin growth, skin maturation, skin barrier formation, wound healing, skin flexibility, and tissue repair. It may also be used as a skin protectant to promote skin barrier formation, skin moisture retention, and skin flexibility.
- the following general synthetic vernix composition A was used, with each component given in % weight (total of 100%):
- composition A Composition A
- Composition B Lipid phase lanolin 2 squalene 3.5 linoleic acid 0.8 cholesterol 6 ceramide III 1.5 beeswax 4.2 capric caprilic triglyceride 1 cholesterol sulfate 1
- composition C Lipid phase lanolin 2 squalene 4 linoleic acid 1 mineral oil 5 cholesterol 4 ceramide III 1 beeswax 3 capric caprilic triglyceride 2 ! PEG30 dipolyhydroxystearat ⁇ (Arlacel P135®) 1.5 sorbitan sesquioleate 0.5
- composition D Lipid phase lanolin 2 squalene 4 linoleic acid 1 mineral oil 3.5 cholesterol 5.5 ceramide III 1 beeswax 3 capric caprilic triglyceride 2
- composition E Lipid phase lanolin 2 squalene 4 linoleic acid 1 mineral oil 3 cholesterol 5.5 ceramide IN 1 beeswax 4.2 capric caprilic triglyceride 1.5 PEG30 dipolyhydroxystearate (Arlacel P135®) 1.5 sorbitan sesquioleate 0.5
- Composition F Lipid phase lanolin 2-3 stearyl alcohol 3-4 beeswax 1-2 mineral oil 6-7 petrolatum 4-6 polyglyceryl-4-isostearate and cetyldimethicone 2 copolyol and hexyl laurate (Abil WE09) cetyl dimethicone copolyol 1 Water phase propylparaben qs. sodium chloride 0.7 glycerin 7 water (deionized) 70
- composition F specific concentrations are 2.7% ⁇ lanolin, 3.5% wt stearyl alcohol, 1.7% ⁇ beeswax, 6.4% ⁇ mineral oil, and 5% ⁇ petrolatum.
- Lanolin is classified chemically as a wax, being a complex mixture of naturally occurring esters and polyesters of thirty-three high molecular weight alcohols (principally sterols) and thirty-six fatty acids. It is 98% ester minimum, of which the fatty alcohols and fatty acids comprise an approximately 50/50 ratio.
- a typical composition of lanolin contains esters of sterols and triterpene alcohols (35.4%), esters of aliphatic alcohols (23.7%), monohydroxyesters of sterols and of triterpene and aliphatic alcohols (20.0%), di- and polyhydroxyesters and free diols (7.9%), free aliphatic alcohols (5.6%), free sterols (4.1 %), free hydrocarbons (0.6%), free fatty acids (0.5%), and unknown components (2.2%).
- compositions A-E the components of the lipid phase except squalene, Arlacel P135® and sorbitan sesquioleate in compositions A-E, and except Abil WE09 and cetyl dimethicone copolyol in composition F, were mixed.
- the mixture was heated on a water bath until it softened and became flowable.
- the temperature of the mixture ranged from about 70 0 C to about 75 0 C.
- the remaining components of the lipid phase were added with continued heating on the water bath until the mixture was completely melted.
- the temperature of the mixture ranged from about 7O 0 C to about 75°C.
- the components of the water phase were mixed.
- the resulting mixture was heated on a water bath until the temperature of the mixture ranged from about 70°C to about 75 0 C.
- the water phase was then slowly added over about three to about five minutes to the melted lipid phase with vigorous stirring. After the water phase had been added and the mixture became homogeneous, the mixture was homogenized using a BioSpec Products homogenizer (Bartlesville OK) at about 15,000 rpm (set at 1 to 1.5 speed; the setting range is 1 to 5 to yield 5,000 rpm to 30,000 rpm) for about 4-5 minutes sufficient to form a viscous emulsion. The mixture was allowed to cool, then it was stored in a closed container under ambient conditions (i.e., about 20 0 C to about 22 0 C).
- Evaporative water loss from the composition over time which may alternatively be expressed as percent water retained in the composition over time, was evaluated. This was done by measuring the water in the composition at intervals over thirty minutes (FIG. 2A) and up to three hours (180 min) (FIGS.
- compositions B, C, D, E, F native vernix
- commercially available agents Eucerin® Beiersdorf AG, Hamburg Germany
- Eucerin® a water-in-oil emulsion
- the ingredients are listed as follows: water, petrolatum, mineral oil, ceresin, lanolin alcohol, methylchloroisothiazolinone, methylisothiazolinone), and CurelTM (Andrew Jergens Co., Cincinnati, OH)
- CurelTM an oil-in-water emulsion
- the ingredients are listed as follows: water, glycerin, distearyldimonium chloride, petrolatum, isopropyl palmitate, cetyl alcohol, dimethicone, fragrance, sodium chloride, methylparaben, propylparaben).
- compositions were spread as a thin film (3.28 mg/cm 2 ) on an aluminum pan (14 mm diameter) weighing dish and immediately weighed on a Cahn C-31 microbalance® (Cahn Instruments, Inc., Cerritos CA). This initial weight was designated Wj nt . Gravimetric measurements were made every two minutes for the first thirty minutes, and every thirty minutes thereafter for three hours (180 min). The weighing dish and composition were then placed in a vacuum desiccator to remove all water in the composition. For samples in which the water content is unknown, the sample was weighed every day for up to seven to ten days or until a constant weight was obtained.
- This final weight was designated W end - Temperature and relative humidity of the room during the period of study were noted. If the relative humidity deviated from about 41 % to about 45%, the experiments were performed in a controlled humidity chamber. A control material was used in all experiments to account for differences in environmental humidity (room conditions) from one experiment to another to allow data comparison. The difference between W int and W end was referred to as the total water content in the composition. These data were used to calculate the initial percent water content in the composition and to obtain the percent water content at each time point. These data were plotted in terms of percent water content remaining in the composition over the period of time.
- Native vernix provided the best water retention, both in its high water content and low rate of water loss. Native vernix contained about
- native vernix contained about 78% w/w water (about a 3% w/w loss in water).
- native vernix contained about 75% w/w water (about a 6% w/w loss in water).
- CurelTM contained about 70% w/w water at zero time. At 180 min, CurelTM contained about 14% w/w water (about a 56% w/w loss in water). Eucerin® contained about 39% w/w water at zero time. At 180 min, Eucerin® contained about 36% w/w water (about a 3% w/w loss in water).
- composition B contained about 73% w/w water at zero time. At 30 min, composition B contained about 67% w/w water (about a 6% w/w loss in water, calculation based on initial percent water). At 180 min, composition B contained about 59% w/w (about a 14% loss in water, calculation based on initial percent water).
- composition C contained about 70% w/w water at zero time. At 30 min, composition C contained about 50% w/w water (about a 20% w/w loss in water, calculation based on initial percent water). At 180 min, composition C contained about 33% w/w water (about a 37% loss in water, calculation based on initial percent water).
- composition D contained about 68% w/w water at zero time. At 30 min, composition D contained about 55% w/w water (about a 13% w/w loss in water, calculation based on initial percent water). At 180 min, composition D contained about 37% w/w water (about a 31% loss in water).
- composition E contained about 70% w/w water at zero time. At 30 min, composition E contained about 61 % w/w water (about a 9% w/w loss in water, calculation based on initial percent water). At 180 min, composition E contained about 48% w/w water (about a 22% loss in water, calculation based on initial percent water).
- composition F contained about 70% w/w water at zero time. At 30 min, composition F contained about 57% w/w water (about a 13% w/w loss in water, calculation based on initial percent water). At 180 min, composition F contained about 39% w/w water (about a 31% loss in water, calculation based on initial percent water).
- the data were obtained by performing regression analyses, one for the time from 0-0.5 hr (0-30 minutes), and the other for the time from 0.5-3 hrs (30-180 minutes).
- the rates were taken as the slopes of the regression lines expressed as change in % water in the composition/change in time.
- the first rate was the change over the first 0.5 hr, and the second rate was the change from 0.5-3 hrs. Therefore, the rate was change in % water/time in hrs.
- the rates were negative in sign because they represented a loss in water. A composition that lost no water would have a value of 0 (the numerator would be 0 and the denominator would be 0.5 or 2.5 hr).
- the first and second rates were, respectively, -5.2% water in composition/hr and -1.5% water in composition/hr.
- the first and second rates were, respectively, -2% water in composition/hr and -0.5% water in composition/hr.
- Eucerin® had a very slow evaporative water loss, similar to vernix, but it had a much lower starting water level, as is subsequently described.
- the inventive compositions had a rate of evaporative water loss during 0-0.5 h from about -38% water in composition/hr up to 0% water in composition/hr, and a rate of evaporative water loss during 0.5-3 hr from about -8% water in composition/hr up to 0% water in composition/hr.
- the upper limit for rate of evaporative water loss during 0-0.5 h was about -1% water in composition/hr
- the upper limit for rate of evaporative water loss during 0.5-3 hr was about -0.2% water in composition/hr.
- WVT Water vapor transport
- inventive compositions as well as native vernix, CurelTM, and Eucerin®.
- ASTM E96E procedure B subsequently described, was used where a cream form of the composition was prepared in a film form and applied to a highly porous and permeable synthetic substrate at 37-38% relative humidity.
- the permeable substrate allowed the permeability characteristics of the composition to be determined without interference from the substrate.
- Water vapor transport through these films was determined as follows. Specifically, four grams of distilled water was added to a hexagonal polystyrene disposable weighing dish (20 mm length x 20 mm width x 10 mm height).
- the dish was completely covered by a substantially highly permeable substrate of which N-terface® (Winfield Laboratories, Inc., Richardson TX) (50 mm x 50 mm) is an example, which was glued with cyanoacrylate applied to the rim of the dish to form a watertight seal.
- N-terface® Winfield Laboratories, Inc., Richardson TX
- the composition to be evaluated was uniformly applied to the outer surface of the substrate by spatula at a concentration of 25 mg/cm 2 .
- the apparatus was maintained at the stated relative humidity. Testing under steady state conditions was performed after two hours of equilibration. Weight loss was measured at zero time, two hours, and four hours. The rate of weight loss, that is, the water vapor transport (WVT), was calculated for each composition
- the water vapor transport for the dish alone was 150 + 4 g/m 2 /hr, and for the substrate alone was 132 + 9 g/m 2 /hr.
- the water vapor transport through vernix was about 19.2 + 4.9 g/m 2 /h.
- the water vapor transport through a water-in-oil emulsion (Eucerin®) was 2.6 + 0.2 g/m 2 /h.
- the water vapor transmission through an oil-in-water emulsion (CurelTM) was 72.0 + 3.0 g/m 2 /h.
- Water vapor transport through composition B was 21.6 + 3.0 g/m 2 /h.
- Water vapor transport through composition C was 20.0 + 0.4 g/m 2 /h.
- Water vapor transport through composition D was 13.4 + 0.4 g/m 2 /h.
- Water vapor transport through composition E was 13.2 + 0.8 g/m 2 /h.
- Water vapor transport through composition F was 18.9 + 1.3 g/m 2 /h.
- Water vapor transport or transmission through the inventive synthetic vernix composition ranged between the percent water vapor transmission through a substantially highly permeable film, such as N-terface ®, and the percent water vapor transmission through a substantially highly occlusive film, such as polytetrafluoroethylene (TEFLON ®) or Saran Wrap ®.
- water vapor transmission of the inventive synthetic vernix composition was between about 85% of the water vapor transmission through a substantially highly permeable film, and about 5% of transmission through a substantially highly occlusive film. That is, water vapor transmission through the synthetic vernix film was in the range that is at least 15% lower than water vapor transmission through a highly permeable film, and at least 5% higher than water vapor transmission through a highly occlusive film. All compositions were stable at room temperature (about 20 0 C) for at least two months without phase separation (i.e., they were phase stable), and without syneresis of the water (beading of water onto the sample surface). There was no change in color.
- compositions thinned over time with slow evaporation of the internal phase water. Evaporation was accelerated if the compositions were not covered. Freeze thaw data were obtained as a technical measure of composition stability.
- the compositions were stressed by freezing at -20 ⁇ 5°C and thawing at +20 ⁇ 5°C over three cycles. The freeze/thaw cycle testing was performed to demonstrate phase stability during temperature stresses, e.g., during shipment, storage, etc. Compositions were placed at a cold temperature (-20 ⁇ 5°C), then placed at a warm temperature (+20 ⁇ 5°C), then returned to a cold temperature. The cycle of cold to warm was repeated three times. The compositions did not separate or change viscosity, and were considered stable for storage, shipment, etc. under various weather conditions.
- the inventive compositions had tactile properties similar to native vernix. Tactile properties were evaluated by individuals experienced in assessing tactile characteristics and using methods known to one skilled in the art, such as when the composition is rubbed between the fingers, and skin feel to which the compositions had been applied. To further characterize the feel of the compositions, the tactile properties were compared with tactile properties of standard oil-in-water and water-in-oil emulsions (data not shown).
- the inventive compositions were thick and viscous with characteristics of a cream, spreadable using a slight force such as that used to apply lotion or cream to the surface of skin to spread on skin, and did not leave a sticky feeling to the skin.
- compositions had rheological properties similar to native vernix. They did not flow under normal gravity. Characteristics observed during handling, spreading, etc were used to evaluate viscosity. The viscosity increased with increasing internal phase (water) because increasing the internal phase and reducing each droplet of internal phase resulted in packing of the composition. Increasing the internal phase (water phase) from about 70% w/w water to about 75% w/w water, for example, does not likely change the viscosity, because the compositions are already viscous. Increasing the internal phase (water phase) from about 30% w/w water to about 70% w/w water, however, resulted in a visually observable increase in viscosity. The viscosity of the inventive compositions was based on the amount of internal phase (water phase), and the type and amount of external phase (lipid).
- the inventive compositions had an overall neutral pH.
- the compositions had a high and uniform water content (e.g., from greater than about 65% w/w to about 82% w/w water). They were highly viscous at room temperature (about 20 0 C to about 22°C). They were highly permeable to water, and only very slowly released water.
- the inventive compositions had a viscosity profile, a rheology profile, penetrability, tactile properties, permeability, and water vapor transport properties that were substantially similar to native vernix.
- Exogenously applied synthetic vernix removes soil from the skin with an effectiveness that was quantitatively at least equivalent to, and may be better than, commercial skin cleansers.
- Synthetic vernix on the skin surface interacts with exogenous cleansing agents such as soaps and/or surfactants, with subsequent flocculation and detachment, consistent with a function of vernix as an endogenous skin cleanser at birth.
- a soap as used herein, is a mixture of sodium salts of long chain fatty acids, typically Ci 2 to Ci 8 fatty acids.
- a surfactant as used herein, is a surface-active substance. Both soaps and surfactants are cleansing agents.
- the cleansing aspects of synthetic vemix Composition B was evaluated in cleansing assays. Synthetic vemix was stored at room temperature until use.
- FIGS. 3A, 3B, and 3C show the unsoiled, carbon-soiled, and synthetic vernix- cleansed skin, respectively, in photographs using a light source that illuminates from above.
- L-score values of volar forearm skin were obtained.
- Adult volar forearm was assessed using Adobe Photoshop L-scale analysis of digital images.
- FIG. 3 data were collected before soiling (baseline), after soiling material was manually rubbed into the skin (soiled), and after cleansing (cleaned).
- the cleansing treatments were either Aquaphor, Johnson & Johnson Baby WashTM, Pond's Cold CreamTM, or vernix.
- FIGS. 4A, 4B, 4C, 4D 1 4E, and 4F for tests with synthetic vernix compared to native vernix. The data demonstrate that all of the tested cleansing agents returned the skin to near baseline L-scale levels.
- FIG. 5 quantitates the results from FIG. 3 as differences in L-scale scores before and after cleansing.
- the data in FIGS. 5 and 5A are (L value after cleansing -L value before soiling).
- a negative value indicated that skin retained some soiling material, with higher negative values indicating more soiling material retained.
- a positive value indicated that the skin was cleaner after the cleansing procedure.
- approximate values for each treatment in tests using synthetic vernix in comparison to native vernix were as follows: Aquaphor -2; synthetic vernix -5.8; Johnson & Johnson Baby WashTM +2.1 ; Pond's Cold CreamTM -0.9; native vernix -4; water -1.1.
- FIGS. 6A1-6A6 show representative images of soiled skin and its black and white counterpart images before treatment with the indicated cleansing agent.
- FIGS. 6B1-6B6 show the respective images after treatment with the cleansing agent.
- the Matlab technical computing software was used to segment the original image into 16 equally sized regions.
- the resultant images are first converted to Gray scale, then a threshold algorithm is performed on the Gray scale images to distinguish between the soiling material and endogenous topographical features of the skin. This process generates the black and white image.
- the comparative cleansing abilities are shown graphically in FIG. 6C.
- vernix As a skin cleansing material. Prenatally, vernix detaches into the amniotic fluid under the influence of pulmonary surfactant. This biological process is similar to self-cleaning (desquamation) of the stratum corneum. Vernix as an endogenous cleanser utilizes this cleansing function for optimal delivery room management during transition of the neonate, either full term or pre-term, to a nonsterile environment.
- the hydrophilic component of vernix aids in removing hydrophilic soils.
- the hydrophobic component of vernix aids in removing hydrophobic soils.
- an exogenous cleanser for the first bath may be tailored to detach soil and endogenous vernix, with vernix detachment either partial or complete as desired.
- a simulated cell component may be used as a vehicle to deliver agents to the skin surface to provide an anti-infective benefit, and also as a vehicle to deliver anti-oxidants such as Vitamin E to the skin.
- actives can be loaded by direct addition to melted lipid or water (i.e., before hydration), or by diffusion into the structure after it is formed.
- the composition may include other skin cleaning agents, and or other components such as emollients, humectants, etc.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Insects & Arthropods (AREA)
- Cosmetics (AREA)
Abstract
A composition and a method of producing a composition which simulates hydration, cleansing and other properties of native vernix. The composition contains hydratable water-in-oil emulsified particles providing water vapor transport and evaporative water loss properties, rheologic, tactile, cleansing, and other properties simulating native vernix. The inventive composition simulates hydrophobic properties of native vernix by a matrix of one or more lipids that are present in native vernix, in which the simulated cells are dispersed. In one embodiment, the lipids are substantially physiologic. Any or all the following lipids may be used, each of which is found in native vernix, and each of which is available commercially : cholesterol esters, ceramides, triglycerides, cholesterol, free fatty acids, phospholipids, wax esters, squalene, wax diesters, and cholesterol sulfate. Other physiologically acceptable lipids, such Petrolatum and/or mineral oil, may be included in some formulations.
Description
SIMULATED VERNIX COMPOSITIONS FOR SKIN CLEANSING AND OTHER APPLICATIONS
Background of the Invention
A composition simulating natural vernix and uses for the composition. Summary of the Invention
One embodiment is a synthetic vernix composition having a continuous lipid phase where the lipids are substantially physiologic lipids, and a water phase of simulated cells dispersed in the lipid phase, the water phase capable of retaining greater than about 65%w/w water of the total composition, with water vapor transport through the composition that ranges between about 85% of water vapor transport through a substantially highly permeable composition and about 5% of water vapor transport through a substantially highly occlusive composition, and a rate of evaporative water
loss from the composition from about -38% water in composition/hr to 0% water in composition/hr from 0 h to 0.5 hr, that is, up to about 38% water loss within the first half-hour, and from about -8% water in composition/hr to 0% water in composition/hr from 0.5 hr to 3 hr, that is, up to about 8% water loss after the first half-hour and for the next two and one-half hours.
Another embodiment is a synthetic vernix composition having a lipid phase and a water phase, with the lipid phase having at least one emulsifying agent to form hydratable water-in-oil emulsified particles. The emulsifying agent has a hydrophile-lipophile balance (HLB) value such that the emulsifying agent does not substantially dissolve in the water phase. For example, the HLB value may range between about 3 to about 6.
In one embodiment, the synthetic vernix composition comprises hydratable water-in-oil emulsified particles having a lipid phase comprising lanolin, squalene, linoleic acid, cholesterol, ceramide III, wax, capric/caprilic triglyceride, cholesterol sulfate; PEG30 dipolyhydroxystearate and sorbitan sesquioleate emulsifying agents; and a water phase containing methylparaben and/or propylparaben, magnesium sulfate, glycerin, and water in concentrations sufficient to provide water vapor transport, evaporative water loss, tactile and rheological properties simulating native vernix. In another embodiment, the synthetic vernix composition comprises hydratable water-in-oil emulsified particles having a lipid phase comprising lanolin, stearyl alcohol, wax, mineral oil, and petrolatum; cetyl dimethicone copolyol and Abil WE09 (polyglyceryl-4-isostearate and cetyl dimethicone copolyol and hexyl laurate) emulsifying agents, and water.
Another embodiment is a method of using synthetic vernix to remove soil from a skin surface. The composition is applied to the soiled surface, then is removed along with the soiling material. The method may be used on a premature or full term infant, a child, an adult, a geriatric patient, and the composition may be used on an intact or compromised surface, such as a wound or ulcer. The method may be used with a synthetic vernix composition that also contains a soap and/or surfactant.
Another embodiment is a method for fully or partially cleansing a baby (full term or premature) immediately after birth with a composition containing synthetic vernix to remove amniotic fluid, endogenous vernix, meconium, blood and other fluids, upon removing the composition.
Another embodiment is a method of cleaning a soiled skin surface by applying a composition consisting essentially of synthetic vernix under conditions to emulsify the soiling material in the vernix, and then removing the vernix and emulsified soiling material. The amount of synthetic vernix may be up to about 16 mg/cm2.
Another embodiment is a method of cleansing skin by applying a nontoxic film having a thickness up to about 16 mg/cm2 and consisting essentially of synthetic vernix to a layer of epithelial cells to provide a skin cleansing effect. The film may be applied either directly or indirectly to the surface; for example, it may be applied to a wash cloth, a wipe, a bandage, a pad, etc. Another embodiment is a method of cleansing an epithelial layer by applying a non-toxic film having a thickness of up to about 16 mg/cm2 and consisting essentially of synthetic vernix to the epithelial layer, and then removing the film from the cleansed tissue.
Another embodiment is a method to protect a skin surface of an individual who is, or may be, susceptible to commercially available cleansing products (e.g., one allergic to some commercial soaps or cleansers). In the method, a composition consisting essentially of synthetic vernix is applied to a skin surface of this individual in an amount up to 16 mg/cm2 before exposing the skin surface to the product.
Another embodiment is a method to remove a soiling material from a skin surface by providing synthetic vernix and at least one soap or surfactant to the soiled surface under conditions resulting in flocculation and detachment of the soil from the surface.
The invention will be further appreciated with respect to the following detailed description, figures, and examples. Brief Description of the Figures
FIG. 1 schematically illustrates simulated cells dispersed in a lipid matrix.
FIGS. 2A, 2B, and 2C show evaporative water loss profiles of embodiments of synthetic vernix.
FIGS. 3A, 3B, and 3C are digital images of volar forearm skin, either unsoiled (FIGS. 3A1 and 3A2, after application of a soiling material (FIGS. 3B1 and 3B2), or after application of a synthetic vernix (FIGS. 3C1 and 3C2).
FIGS. 4A, 4B, 4C, 4D, 4E, and 4F are histograms quantitating the amount of soiling material on the skin surface of unsoiled (baseline), soiled, and cleansed skin treated with water (FIG. 4A), Aquaphor (FIG. 4B), commercial cleansers (FIGS. 4C, 4D), synthetic vernix (FlG. 4E), and native vernix (FIG. 4F).
FIG. 5 is a plot of differences in L-scale scores before and after cleansing with various treatments.
FIGS. 6A1-6A6, 6B1-6B6, and 6C are representative digital images converted to black and white counterpart images and graphical results of skin treated with synthetic vernix and other cleansing agents. Detailed Description
A nontoxic simulated vernix composition, also referred to herein as synthetic vernix, contains a component of simulated cells and a component of at least one lipid. The inventive composition simulates the hydration, barrier, rheological, tactile, and other properties of native vernix. With respect to its hydration properties, native vernix provides both hydrophilic properties from the water associated with its cellular component, and hydrophobic properties from its lipid component. The inventive composition simulates hydrophilic properties of native vernix by hydrated emulsified water droplets, referred to herein as emulsified particles, that have the capability to retain, in a hydrated state, at least 65%^ water in the composition in their internal (water) phase. The inventive composition simulates hydrophobic properties of native vernix by a matrix of one or more lipids that are present in native vernix, in which the simulated cells are dispersed. In one embodiment, the lipids are substantially physiologic. The inventive composition thus retains or is capable of retaining water at a concentration that simulates native vernix, and transports water vapor at a rate that simulates native vernix.
Native vernix, as used herein, encompasses vernix as it is obtained from a newborn, as well as vernix obtained from a newborn that has been rendered tractable, as described in U.S. Patent Nos. 5,989,577;
6,113,932; 6,333,041; and U.S. Patent application Serial Nos. 09/850,844 (now U.S. Patent No. 6,562,358); 10/241 ,184; 60/377,430 and 60/439,966; and PCT application Serial No. PCT/US03/13612, now U.S. Patent application Serial No. 10/512,933, each of which is expressly incorporated by reference herein in its entirety.
In the inventive composition, the cell component of native vernix , is replaced by hydratable emulsified particles that perform the hydration functions of cells; these structures may be termed "simulated cells" or "synthetic cells". The "cellular" component, also referred to herein as simulated cells, hydrates a surface to which the inventive composition is applied. It does this by slowly releasing water and by transporting water vapor, as cells do in native vernix. The simulated cells in small particle form are mixed into a lipid matrix. The lipid matrix contains at least one commercially available lipid that is present in native vernix. Any or all of the following lipids may be used, each of which is found in native vernix, and each of which is available commercially (for > example, Sigma, St. Louis MO): cholesterol esters, ceramides, triglycerides, cholesterol, free fatty acids, phospholipids, wax esters, squalene, wax diesters, and cholesterol sulfate. The composition of the lipid phase may be varied to provide the desired spreading characteristics and viscosity for the final composition. For example, a relatively higher wax content will produce a less spreadable, more viscous composition than a relatively lower wax content; a relatively higher free fatty acid and/or triglyceride content will produce a more easily
spreadable, less viscous composition than a relatively lower free fatty acid and/or triglyceride content.
Phase stable water-in-oil emulsions in small particle form in a lipid matrix provided compositions that simulated native vernix. This is shown schematically in FIG. 1 where water droplets 10 exist in a lipid matrix 20, the water droplets 10 packaged in particles 30 as emulsions. The synthetic vernix compositions substantially duplicated properties of native vernix. The emulsified particles performed the function of the biological cells in native vernix with respect to regulating water transport, permeability, barrier, water- loss, and other properties relating to water behavior. The emulsions effectively allowed the water to exist in droplets, i.e., packaged as droplets.
Emulsifying agents or emulsifiers are generally considered to be surface active agents or surfactants. While the term surfactant may refer to cleaning ability, in the case of the inventive compositions hydrophile-lipophile balance (HLB) is used to describe the nature of the emulsifier. The HLB of the emulsifier is selected so as to keep the water retained within the particular matrix of the formulation. If the HLB is too high, the emulsifier will dissolve in the water and therefore not keep the water as droplets within the lipid matrix. HLB is a property represented on an arbitrary scale of 0-20 for non- ionic surfactants, withhigher numbers indicating the most hydrophilic surface active agents, and lower numbers indicating the most hydrophobic surface active agents. The HLB of a nonionic surfactant is the approximate weight of ethylene oxide in the surfactant divided by 5. For example, polyoxyethylene derivatives of Spans (Tweens) have relatively higher HLB values in the range of about 9.6 to about 16.7, while sorbitan esters (Spans) have relatively lower HLB values
in the range of about 1.8 to about 8.6. As other examples, the HLB of oleic acid is 1 ; the HLB of glyceryl monostearate (Span 80) is 3.8; the HLB of sorbitan monooleate (Span 20) is 4.3; the HLB of triethanolamine oleate is 12.0; the HLB of polyoxyethylene sorbitan is 15; the HLB of monooleate (Tween 80) polyoxyethylene sorbitan is 16.7; the HLB of monolaurate (Tween 20) sodium oleate is 18.0; the HLB of sodium lauryl sulfate is 40.
In the inventive composition, the HLB values of the emulsifying agents ranged from lower than 4 to about 6. In one embodiment, the HLB ranged from 3.8 to 6.0. In one embodiment, the HLB was about 3.8. These emulsifying agents provided a high internal phase (i.e., water phase) system, containing water as greater than about 65%w/w of its total volume, and yielded a water loss profile simulating native vernix.
In one embodiment the emulsifying agents were polyhydroxy hydrocarbons. In another embodiment the emulsifying agents were the non-
ionic PEG-7 hydrogenated castor oil (Cremophore WO7®) (4%w/w), or polyglyceryl-4 isostearate and cetyl dimethicone copolyol and hexyl laurate (Abil WE09) (5%w/w). In another embodiment the emulsifying agents were cremophore WO7 (0.8%w/w) and cetyl dimethicone copolyol (2%w/w). In another embodiment the emulsifying agents were cetyl dimethicone copolyol (1 %w/w) and Abil WE 09 (2%w/w). In another embodiment, the emulsifying agent was Abil WE 09 (2%w/w). In another embodiment the emulsifying agents were PEG-30 dipolyhydroxystearate (Arlacel P 135®, Uniqema, USA) (about 1.5%w/w) and sorbitan sesquioleate (Uniqema) (about 0.5%w/w). In another embodiment, the emulsifying agent is polyglyceryl-3-diisostearate (Unichema, Gouda, NL) and cetyl dimethicone copolyol. In another
embodiment, the emulsifying agent is polyglyceryl-3-oleate (Danisco AJS, Copenhagen DK). In another embodiment, the emulsifying agent is polyglyceryl-4-isostearate (about 2.5%w/w to about 4%w/w) (ISOLAN Gl 34, Goldschmidt, Mannheim, DE). In another embodiment, emulsifying agent(s) is/are used with methyl glucose isostearate (about 2%w/w to about 5%w/w) (ISOLAN IS, Goldschmidt) as a co-emulsifier.
In one embodiment, the emulsifying agents were selected to minimize irritancy when the inventive composition was applied to a skin surface. As known to one skilled in the art, "low irritancy" materials cause little or no irritation in skin irritancy testing and among individuals with irritated skin, reactive skin conditions, or with susceptibility to skin irritation. Therefore, skin care product ingredients can be classified according to their effects on skin in standard testing. One irritancy test is the Human Patch Test. The materials to be evaluated are applied under an occlusive patch and left on the skin for up to 24 hours. Following application, the skin condition is evaluated by standard methods, such as dryness and erythema scoring using visual grading scales or instrumental measurement of skin barrier integrity and function. Low irritancy materials have relatively low Patch Test scores, e.g., 0.2-0.5 on a 0-4 scale, and/or cause substantially no irritation in a large population of healthy subjects. In one embodiment of the inventive composition, emulsifiers with low irritancy were selected over emulsifiers that yielded a stable product but that had the potential to cause low levels of irritation in irritated skin populations.
Physiologic lipids that are found in native vernix were incorporated in the formulation to constitute the lipid matrix. These included cholesterol and
squalene (both from Sigma Aldrich, St. Louis, MO), ceramide III (Cosmoferm, NL), cholesterol sulfate (Acros Organics, Leicestershire, UK), linoleic acid (Henkel Corporation-Emery Group, Cincinnati OH), lanolin (Amerchol, Midland Ml), triglyceride (e.g., capric caprilic triglyceride) (Henkel), and wax (e.g. beeswax USP). Other physiologically acceptable lipids, such as Petrolatum® (CVS, Woonsocket, Rl) and/or mineral oil, may be included in some formulations.
The inventive simulated vernix composition retained, or was capable of retaining, greater than about 65% water of the total composition by weight in its internal (water) phase. Additional components may assist in maintaining the emulsion, providing hydration, etc. For example, the water phase may contain electrolytes. In one embodiment, the water phase contained magnesium sulfate (The PQ Corp, Berwyn, PA) which binds water, assists in water release properties of the synthetic cell, and stabilizes the water-in-oil emulsion. In another embodiment, the water phase contained glycerin (Cognis, Cincinnati, OH). Glycerin has a high affinity for water and therefore assists with slow release of the water; it also binds water to the skin surface. In another embodiment, the water phase contained a preservative such as methylparaben and/or propylparaben (Chatham ISP Sutton Laboratories, Wayne NJ). In one embodiment, the inventive composition is applied to a physiologically acceptable support structure in a liquid state to form a film. It is presented as .droplets which coalesce to form a film upon encountering the support. A film is defined herein as an interfacial surface covering, in either a liquid or a solid state, with temperature-dependant properties. Film-forming
techniques include but are not limited to spraying, extruding, blowing, pouring, evaporating, coating and painting.
In an alternate embodiment, a preformed film of the inventive composition is applied to a physiologically acceptable support. The physiologically acceptable support is one that can withstand sterilization, preferably by standard sterilization techniques known to one skilled in the art such as exposing to gamma radiation, autoclaving, and so on. The support is not limited to a particular composition or configuration and, depending upon its use, may or may not be sterilized and may take various forms. In one embodiment, the film is used to enhance skin cell maturation and may be applied to structures such as filters, membranes, beads, particles, and so on. Similarly, the support structure is not limited to a particular state of matter and may be a solid, a semi-solid, a gel and so on. In one embodiment, the support consists of a nylon monofilament interpositional surfacing material such as N-terface® pads (Winfield Laboratories, Inc., Richardson TX), Biobrane II® (Sterling Drug Inc., New York NY) or circular nylon filters of suitable porosity (Micron Separations Inc., Westboro MA). Other support materials, however, may also be used to practice the invention.
In another embodiment, the film of the inventive composition is used to promote wound healing and/or tissue repair. It may be applied to various materials for placement either in direct contact or indirect contact with an intact or compromised skin site requiring treatment, such as a wound, an abrasion, an ulcer, a burned area, a site of infection or irritation, a wart, etc. The support may be permeable to physical and/or chemical agents, and may take a variety of forms, depending upon its purpose and the extent of the area
requiring dressing or treatment. The film may be applied to various synthetics such as thermoplastic films, blown films and breathable films, and various natural and synthetic fabric compositions such as woven, non-woven, spun, and stitched fabrics. The invention may be used in a variety of products, examples of which include wound dressings and coverings such as bandages, tapes, gauze, adhesive products applied for a short or long term to the skin, ostomy care products, hospital pads such as incontinent pads, absorbent pads, and examination pads, disposable and cloth diapers, and feminine hygiene products such as intralabial devices. The inventive composition may be used therapeutically to promote skin growth, skin maturation, skin barrier formation, wound healing, skin flexibility, and tissue repair. It may also be used as a skin protectant to promote skin barrier formation, skin moisture retention, and skin flexibility. In one embodiment, the following general synthetic vernix composition A was used, with each component given in % weight (total of 100%):
Composition A
Lipid phase lanolin 1.5 - 2 squalene 3.2 - 5.8 linoleic acid 0.8 - 1.5 mineral oil 0 - 5 cholesterol 4 - 6 ceramide III 0.7 - 1.5 beeswax 3 - 4.2 capric/caprilic triglyceride 1 - 2 cholesterol sulfate 0-3
PEG30 dipolyhydroxystearate (Arlacel P135®) 1.5 sorbitan sesquioleate 0.5
Water phase methylparaben qs. magnesium sulfate 0.5 glycerin 2.5 - 5 water (deionized) 70.5 - 75
In another embodiment, the following synthetic vernix composition B was used, with each component given in % weight (total of 100%):
Composition B Lipid phase lanolin 2 squalene 3.5 linoleic acid 0.8 cholesterol 6 ceramide III 1.5 beeswax 4.2 capric caprilic triglyceride 1 cholesterol sulfate 1
PEG30 dipolyhydroxystearate (Arlacel P135®) 1.5 sorbitan sesquioleate 0.5
Water phase methylparaben, propylparaben qs. magnesium sulfate 0.5 glycerin 2.5 water (deionized) 75
In another embodiment, the following synthetic vernix composition C was used, with each component given in % weight (total of 100%):
Composition C Lipid phase lanolin 2 squalene 4 linoleic acid 1 mineral oil 5 cholesterol 4 ceramide III 1 beeswax 3 capric caprilic triglyceride 2 !
PEG30 dipolyhydroxystearatθ (Arlacel P135®) 1.5 sorbitan sesquioleate 0.5
Water phase methylparaben, propylparaben qs. magnesium sulfate 0.5 glycerin 5 water (deionized) 70.5
In another embodiment, the following synthetic vernix composition D was used, with each component given in % weight (total of 100%):
Composition D Lipid phase lanolin 2 squalene 4 linoleic acid 1 mineral oil 3.5 cholesterol 5.5 ceramide III 1 beeswax 3 capric caprilic triglyceride 2
PEG30 dipolyhydroxystearate (Arlacel P135®) 1.5 sorbitan sesquioleate 0.5
Water phase methylparaben, propylparaben qs. magnesium sulfate 0.5 glycerin 5 water (deionized) 70.5
In another embodiment, the following synthetic vernix composition E was used, with each component given in % weight (total of 100%):
Composition E Lipid phase lanolin 2 squalene 4 linoleic acid 1 mineral oil 3 cholesterol 5.5
ceramide IN 1 beeswax 4.2 capric caprilic triglyceride 1.5 PEG30 dipolyhydroxystearate (Arlacel P135®) 1.5 sorbitan sesquioleate 0.5
Water phase methylparaben, propylparaben qs. magnesium sulfate 0.5 glycerin 5 water (deionized) 70.5
In another embodiment, the following synthetic vernix composition F was used, with each component given in % weight (total of 100%):
Composition F Lipid phase lanolin 2-3 stearyl alcohol 3-4 beeswax 1-2 mineral oil 6-7 petrolatum 4-6 polyglyceryl-4-isostearate and cetyldimethicone 2 copolyol and hexyl laurate (Abil WE09) cetyl dimethicone copolyol 1 Water phase propylparaben qs. sodium chloride 0.7 glycerin 7 water (deionized) 70
In one embodiment of composition F, specific concentrations are 2.7%^ lanolin, 3.5%wt stearyl alcohol, 1.7%^ beeswax, 6.4%^ mineral oil, and 5%^ petrolatum.
Lanolin is classified chemically as a wax, being a complex mixture of naturally occurring esters and polyesters of thirty-three high molecular weight alcohols (principally sterols) and thirty-six fatty acids. It is 98% ester minimum, of which the fatty alcohols and fatty acids comprise an
approximately 50/50 ratio. A typical composition of lanolin contains esters of sterols and triterpene alcohols (35.4%), esters of aliphatic alcohols (23.7%), monohydroxyesters of sterols and of triterpene and aliphatic alcohols (20.0%), di- and polyhydroxyesters and free diols (7.9%), free aliphatic alcohols (5.6%), free sterols (4.1 %), free hydrocarbons (0.6%), free fatty acids (0.5%), and unknown components (2.2%).
In formulating the inventive compositions, the components of the lipid phase except squalene, Arlacel P135® and sorbitan sesquioleate in compositions A-E, and except Abil WE09 and cetyl dimethicone copolyol in composition F, were mixed. The mixture was heated on a water bath until it softened and became flowable. The temperature of the mixture ranged from about 700C to about 750C. The remaining components of the lipid phase were added with continued heating on the water bath until the mixture was completely melted. The temperature of the mixture ranged from about 7O0C to about 75°C.
The components of the water phase were mixed. The resulting mixture was heated on a water bath until the temperature of the mixture ranged from about 70°C to about 750C.
The water phase was then slowly added over about three to about five minutes to the melted lipid phase with vigorous stirring. After the water phase had been added and the mixture became homogeneous, the mixture was homogenized using a BioSpec Products homogenizer (Bartlesville OK) at about 15,000 rpm (set at 1 to 1.5 speed; the setting range is 1 to 5 to yield 5,000 rpm to 30,000 rpm) for about 4-5 minutes sufficient to form a viscous
emulsion. The mixture was allowed to cool, then it was stored in a closed container under ambient conditions (i.e., about 200C to about 220C).
This procedure was used to prepare 10 grams of the inventive composition; hence, parameters such as the time of mixing may be varied for other amounts, as known to one skilled in the art.
The invention will be further appreciated with reference to the following examples.
EXAMPLE 1
Evaporative water loss from the composition over time, which may alternatively be expressed as percent water retained in the composition over time, was evaluated. This was done by measuring the water in the composition at intervals over thirty minutes (FIG. 2A) and up to three hours (180 min) (FIGS. 2B and 2C) and calculating the percent of water for embodiments of the inventive composition (compositions B, C, D, E, F), native vernix, and the commercially available agents Eucerin® (Beiersdorf AG, Hamburg Germany) (a water-in-oil emulsion; the ingredients are listed as follows: water, petrolatum, mineral oil, ceresin, lanolin alcohol, methylchloroisothiazolinone, methylisothiazolinone), and Curel™ (Andrew Jergens Co., Cincinnati, OH) (an oil-in-water emulsion; the ingredients are listed as follows: water, glycerin, distearyldimonium chloride, petrolatum, isopropyl palmitate, cetyl alcohol, dimethicone, fragrance, sodium chloride, methylparaben, propylparaben).
To assess evaporative water loss from each of the compositions, the compositions were spread as a thin film (3.28 mg/cm2) on an aluminum pan (14 mm diameter) weighing dish and immediately weighed on a Cahn C-31
microbalance® (Cahn Instruments, Inc., Cerritos CA). This initial weight was designated Wjnt. Gravimetric measurements were made every two minutes for the first thirty minutes, and every thirty minutes thereafter for three hours (180 min). The weighing dish and composition were then placed in a vacuum desiccator to remove all water in the composition. For samples in which the water content is unknown, the sample was weighed every day for up to seven to ten days or until a constant weight was obtained. This final weight was designated Wend- Temperature and relative humidity of the room during the period of study were noted. If the relative humidity deviated from about 41 % to about 45%, the experiments were performed in a controlled humidity chamber. A control material was used in all experiments to account for differences in environmental humidity (room conditions) from one experiment to another to allow data comparison. The difference between Wint and Wend was referred to as the total water content in the composition. These data were used to calculate the initial percent water content in the composition and to obtain the percent water content at each time point. These data were plotted in terms of percent water content remaining in the composition over the period of time.
Native vernix provided the best water retention, both in its high water content and low rate of water loss. Native vernix contained about
81 %w/w water at zero time. At 30 min, native vernix contained about 78%w/w water (about a 3%w/w loss in water). At 180 min, native vernix contained about 75%w/w water (about a 6%w/w loss in water).
Curel™ contained about 70%w/w water at zero time. At 180 min, Curel™ contained about 14%w/w water (about a 56%w/w loss in water).
Eucerin® contained about 39%w/w water at zero time. At 180 min, Eucerin® contained about 36%w/w water (about a 3%w/w loss in water).
Composition B contained about 73%w/w water at zero time. At 30 min, composition B contained about 67%w/w water (about a 6%w/w loss in water, calculation based on initial percent water). At 180 min, composition B contained about 59%w/w (about a 14% loss in water, calculation based on initial percent water).
Composition C contained about 70%w/w water at zero time. At 30 min, composition C contained about 50%w/w water (about a 20%w/w loss in water, calculation based on initial percent water). At 180 min, composition C contained about 33%w/w water (about a 37% loss in water, calculation based on initial percent water).
Composition D contained about 68%w/w water at zero time. At 30 min, composition D contained about 55%w/w water (about a 13%w/w loss in water, calculation based on initial percent water). At 180 min, composition D contained about 37%w/w water (about a 31% loss in water).
Composition E contained about 70%w/w water at zero time. At 30 min, composition E contained about 61 %w/w water (about a 9%w/w loss in water, calculation based on initial percent water). At 180 min, composition E contained about 48%w/w water (about a 22% loss in water, calculation based on initial percent water).
Composition F contained about 70%w/w water at zero time. At 30 min, composition F contained about 57%w/w water (about a 13%w/w loss in water, calculation based on initial percent water). At 180 min, composition F
contained about 39%w/w water (about a 31% loss in water, calculation based on initial percent water).
The rates of evaporative water loss from the composition over the first thirty minutes (from 0 to 0.5 hour), and then over the next two and one-half hours (from 0.5 to 3 hours), for each of the above compositions are summarized in the following table:
Rate of Evaporative Water Loss
The rates were calculated from the data collected at intervals over 180 minutes (3 hours). This calculation was performed to quantify the shape of the curve of evaporative water loss, as shown in FIGS. 2A-C.
The data were obtained by performing regression analyses, one for the time from 0-0.5 hr (0-30 minutes), and the other for the time from 0.5-3 hrs (30-180 minutes). The rates were taken as the slopes of the regression lines expressed as change in % water in the composition/change in time. The first rate was the change over the first 0.5 hr, and the second rate was the change from 0.5-3 hrs. Therefore, the rate was change in % water/time in hrs. The rates were negative in sign because they represented
a loss in water. A composition that lost no water would have a value of 0 (the numerator would be 0 and the denominator would be 0.5 or 2.5 hr).
For native vernix, the first and second rates were, respectively, -5.2% water in composition/hr and -1.5% water in composition/hr. For Eucerin®, the first and second rates were, respectively, -2% water in composition/hr and -0.5% water in composition/hr. Eucerin® had a very slow evaporative water loss, similar to vernix, but it had a much lower starting water level, as is subsequently described.
The inventive compositions had a rate of evaporative water loss during 0-0.5 h from about -38% water in composition/hr up to 0% water in composition/hr, and a rate of evaporative water loss during 0.5-3 hr from about -8% water in composition/hr up to 0% water in composition/hr. In one embodiment, the upper limit for rate of evaporative water loss during 0-0.5 h was about -1% water in composition/hr, and the upper limit for rate of evaporative water loss during 0.5-3 hr was about -0.2% water in composition/hr.
Water vapor transport (WVT) through the compositions was also evaluated for the inventive compositions, as well as native vernix, Curel™, and Eucerin®. A modification of ASTM E96E, procedure B subsequently described, was used where a cream form of the composition was prepared in a film form and applied to a highly porous and permeable synthetic substrate at 37-38% relative humidity. The permeable substrate allowed the permeability characteristics of the composition to be determined without interference from the substrate. Water vapor transport through these films was determined as follows.
Specifically, four grams of distilled water was added to a hexagonal polystyrene disposable weighing dish (20 mm length x 20 mm width x 10 mm height). The dish was completely covered by a substantially highly permeable substrate of which N-terface® (Winfield Laboratories, Inc., Richardson TX) (50 mm x 50 mm) is an example, which was glued with cyanoacrylate applied to the rim of the dish to form a watertight seal. The composition to be evaluated was uniformly applied to the outer surface of the substrate by spatula at a concentration of 25 mg/cm2. The apparatus was maintained at the stated relative humidity. Testing under steady state conditions was performed after two hours of equilibration. Weight loss was measured at zero time, two hours, and four hours. The rate of weight loss, that is, the water vapor transport (WVT), was calculated for each composition
in terms of weight per unit area per time (g/m2/h). Temperature and relative humidity of the room during the period of study were recorded. The results of WVT at two hours are shown in the following table.
Composition (25 mα/cm2) WVT (q/m2/h) native vernix 19.2 ± 4.9
Eucerin® 2.6 ± 0.2
Curel™ 72.0 ± 3.0 composition B 21.6 ± 3.0 composition C 20.0 ± 0.4 composition D 13.4 ± 0.4 composition E 13.2 ± 0.8 composition F 18.9+ 1.3
For comparison, the water vapor transport for the dish alone (no substrate) was 150 + 4 g/m2/hr, and for the substrate alone was 132 + 9 g/m2/hr. The water vapor transport through vernix was about 19.2 + 4.9 g/m2/h. The water vapor transport through a water-in-oil emulsion (Eucerin®)
was 2.6 + 0.2 g/m2/h. The water vapor transmission through an oil-in-water emulsion (Curel™) was 72.0 + 3.0 g/m2/h. Water vapor transport through composition B was 21.6 + 3.0 g/m2/h. Water vapor transport through composition C was 20.0 + 0.4 g/m2/h. Water vapor transport through composition D was 13.4 + 0.4 g/m2/h. Water vapor transport through composition E was 13.2 + 0.8 g/m2/h. Water vapor transport through composition F was 18.9 + 1.3 g/m2/h. Water vapor transport or transmission through the inventive synthetic vernix composition ranged between the percent water vapor transmission through a substantially highly permeable film, such as N-terface ®, and the percent water vapor transmission through a substantially highly occlusive film, such as polytetrafluoroethylene (TEFLON ®) or Saran Wrap ®. In one embodiment, water vapor transmission of the inventive synthetic vernix composition was between about 85% of the water vapor transmission through a substantially highly permeable film, and about 5% of transmission through a substantially highly occlusive film. That is, water vapor transmission through the synthetic vernix film was in the range that is at least 15% lower than water vapor transmission through a highly permeable film, and at least 5% higher than water vapor transmission through a highly occlusive film. All compositions were stable at room temperature (about 200C) for at least two months without phase separation (i.e., they were phase stable), and without syneresis of the water (beading of water onto the sample surface). There was no change in color. The compositions thinned over time with slow evaporation of the internal phase water. Evaporation was accelerated if the compositions were not covered.
Freeze thaw data were obtained as a technical measure of composition stability. The compositions were stressed by freezing at -20±5°C and thawing at +20±5°C over three cycles. The freeze/thaw cycle testing was performed to demonstrate phase stability during temperature stresses, e.g., during shipment, storage, etc. Compositions were placed at a cold temperature (-20±5°C), then placed at a warm temperature (+20±5°C), then returned to a cold temperature. The cycle of cold to warm was repeated three times. The compositions did not separate or change viscosity, and were considered stable for storage, shipment, etc. under various weather conditions.
The inventive compositions had tactile properties similar to native vernix. Tactile properties were evaluated by individuals experienced in assessing tactile characteristics and using methods known to one skilled in the art, such as when the composition is rubbed between the fingers, and skin feel to which the compositions had been applied. To further characterize the feel of the compositions, the tactile properties were compared with tactile properties of standard oil-in-water and water-in-oil emulsions (data not shown). The inventive compositions were thick and viscous with characteristics of a cream, spreadable using a slight force such as that used to apply lotion or cream to the surface of skin to spread on skin, and did not leave a sticky feeling to the skin.
The compositions had rheological properties similar to native vernix. They did not flow under normal gravity. Characteristics observed during handling, spreading, etc were used to evaluate viscosity. The viscosity increased with increasing internal phase (water) because increasing the
internal phase and reducing each droplet of internal phase resulted in packing of the composition. Increasing the internal phase (water phase) from about 70%w/w water to about 75%w/w water, for example, does not likely change the viscosity, because the compositions are already viscous. Increasing the internal phase (water phase) from about 30%w/w water to about 70%w/w water, however, resulted in a visually observable increase in viscosity. The viscosity of the inventive compositions was based on the amount of internal phase (water phase), and the type and amount of external phase (lipid).
The inventive compositions had an overall neutral pH. The compositions had a high and uniform water content (e.g., from greater than about 65%w/w to about 82%w/w water). They were highly viscous at room temperature (about 200C to about 22°C). They were highly permeable to water, and only very slowly released water. The inventive compositions had a viscosity profile, a rheology profile, penetrability, tactile properties, permeability, and water vapor transport properties that were substantially similar to native vernix.
Exogenously applied synthetic vernix removes soil from the skin with an effectiveness that was quantitatively at least equivalent to, and may be better than, commercial skin cleansers. Synthetic vernix on the skin surface interacts with exogenous cleansing agents such as soaps and/or surfactants, with subsequent flocculation and detachment, consistent with a function of vernix as an endogenous skin cleanser at birth. A soap, as used herein, is a mixture of sodium salts of long chain fatty acids, typically Ci2 to Ci8 fatty acids. A surfactant, as used herein, is a surface-active substance. Both soaps and surfactants are cleansing agents.
The cleansing aspects of synthetic vemix Composition B was evaluated in cleansing assays. Synthetic vemix was stored at room temperature until use. Ten mg of soiling material in the form of uniform black carbon particles (toner from a photocopier) were applied to normal adult volar skin (area=16 cm2). In some embodiments, a photographic image of the pre- soiled skin was recorded. This was followed by manual application and removal (gently wiping the area with a dry 4 in x 4 in gauze pad) of about 12.5 mg/cm2 of synthetic vernix, or selected skin cleansers (Pond's Cold Cream™ and Johnson & Johnson Baby Wash™). Removal of soil was quantified as a change in light intensity, using L-scale analysis of digital images of the cleansed skin.
Digital images of adult volar forearm were recorded at 3Ox magnification using a Skin Surface Analyzer (Moritex USA, Inc.), which captures digital images between 10x through 70Ox magnification and can be operated using two different modes of illumination. One mode supplies light en faces, rendering precise surface detail. The second mode illuminates the skin via back-scattered light, resulting in polarization of the light source; this is useful when specular reflectance from the skin surface interferes with image analysis. For the cleansing assay, 10 mg of the previously described soiling material was uniformly applied to pre-cleaned normal adult volar forearm skin (area=16 cm2). This was followed by manual application and removal of 12.5 mg/cm2 of synthetic vernix, 12.5 mg/cm2 of irradiated isolated native vernix, Pond's Cold Cream™, Johnson & Johnson Baby Wash™, water, or Aquaphor. All applications and removals used manual pressure under routine
conditions. High resolution digital photographs were obtained with a Kodak DCS 420C digital camera before and after applying the soiling material, and after cleansing.
Digital images obtained during cleansing were analyzed to assess efficacy of vernix and the two commercially available topical cleansing preparations. Soil removal was quantified by processing the images in two ways. In one way, the change in light intensity was quantitated using Adobe Photoshop L-scale analysis. In the other way, a program was written using Matlab technical computing software (The Math Works, Natick MA), whereby the original digital image was first segmented into 16 equally sized regions and then converted to Gray scale. A threshold algorithm was performed on each region to distinguish between soiling material and background features of the skin. This process generated a black and white image that was used to calculate the percent of the region that was covered with the soiling material. FIG. 3 demonstrates the cleansing capacity of synthetic vernix.
FIGS. 3A, 3B, and 3C show the unsoiled, carbon-soiled, and synthetic vernix- cleansed skin, respectively, in photographs using a light source that illuminates from above.
To quantitate the amount of soiling material on the skin surface, L-score values of volar forearm skin were obtained. Adult volar forearm was assessed using Adobe Photoshop L-scale analysis of digital images. With reference to FIG. 3, data were collected before soiling (baseline), after soiling material was manually rubbed into the skin (soiled), and after cleansing (cleaned). The cleansing treatments were either Aquaphor, Johnson & Johnson Baby Wash™, Pond's Cold Cream™, or vernix. The results are
shown in FIGS. 4A, 4B, 4C, 4D1 4E, and 4F for tests with synthetic vernix compared to native vernix. The data demonstrate that all of the tested cleansing agents returned the skin to near baseline L-scale levels.
FIG. 5 quantitates the results from FIG. 3 as differences in L-scale scores before and after cleansing. The data in FIGS. 5 and 5A are (L value after cleansing -L value before soiling). A negative value indicated that skin retained some soiling material, with higher negative values indicating more soiling material retained. A positive value indicated that the skin was cleaner after the cleansing procedure. As shown in FIG. 5, approximate values for each treatment in tests using synthetic vernix in comparison to native vernix (FIGS. 4A-4F), were as follows: Aquaphor -2; synthetic vernix -5.8; Johnson & Johnson Baby Wash™ +2.1 ; Pond's Cold Cream™ -0.9; native vernix -4; water -1.1.
FIGS. 6A1-6A6 show representative images of soiled skin and its black and white counterpart images before treatment with the indicated cleansing agent. FIGS. 6B1-6B6 show the respective images after treatment with the cleansing agent. The Matlab technical computing software was used to segment the original image into 16 equally sized regions. The resultant images are first converted to Gray scale, then a threshold algorithm is performed on the Gray scale images to distinguish between the soiling material and endogenous topographical features of the skin. This process generates the black and white image. The comparative cleansing abilities are shown graphically in FIG. 6C.
The data for synthetic vernix demonstrated that all the cleansing agents performed well and demonstrated the cleansing capacity for synthetic vernix. It was noted that there was inter-subject variability in the amount and
depth of dermatogyphics, that spreading of soiling material and the skin's affinity for soil retention were affected by pore size and skin surface oiliness, and that hair and areas of hyperpigmentation may affect Matlab and L score results.
Among the clinical implications of the invention are the in vitro use of synthetic vernix as a skin cleansing material. Prenatally, vernix detaches into the amniotic fluid under the influence of pulmonary surfactant. This biological process is similar to self-cleaning (desquamation) of the stratum corneum. Vernix as an endogenous cleanser utilizes this cleansing function for optimal delivery room management during transition of the neonate, either full term or pre-term, to a nonsterile environment. The hydrophilic component of vernix aids in removing hydrophilic soils. The hydrophobic component of vernix aids in removing hydrophobic soils. The choice of an exogenous cleanser for the first bath may be tailored to detach soil and endogenous vernix, with vernix detachment either partial or complete as desired. Other variations or embodiments of the invention will also be apparent to one of ordinary skill in the art from the above description. For example, a simulated cell component may be used as a vehicle to deliver agents to the skin surface to provide an anti-infective benefit, and also as a vehicle to deliver anti-oxidants such as Vitamin E to the skin. As another example, actives can be loaded by direct addition to melted lipid or water (i.e., before hydration), or by diffusion into the structure after it is formed. The composition may include other skin cleaning agents, and or other components such as emollients, humectants, etc. Thus, the forgoing embodiments are not to be construed as limiting the scope of this invention. What is claimed is:
Claims
1. A simulated vernix composition comprising a continuous lipid phase consisting essentially of physiologic lipids, and a hydratable water phase of simulated cells dispersed in the lipid phase, the hydratable water phase capable of retaining greater than about 65%w/w water of the total composition, said composition in a hydrated film form having a water vapor transmission rate that is between about 85% of the transmission rate through a substantially highly permeable film and about 5% of the transmission rate through a substantially highly occlusive film by a modified ASTM E96E procedure B, and having up to about 38% evaporative water loss from 0 h to 0.5 hr, and up to about 8% evaporative water loss from 0.5 hr to 3 hr.
2. The composition of claim 1 wherein the simulated cells are emulsified particles.
3. The composition of claim 1 wherein the simulated cells are water-in-oil emulsified particles.
4. The composition of claim 3 further comprising an emulsifying agent having a hydrophile-lipophile balance (HLB) to provide water-in-oil emulsified particles.
5. The composition of claim 4 wherein the HLB ranges between about 3 to about 6.
6. The composition of claim 4 wherein the HLB ranges between about 3.5 to about 6.0.
7. The composition of claim 4 wherein the HLB ranges between 3.8 to about 6.0.
8. The composition of claim 4 wherein the emulsifying agent is selected from the group consisting of polyhydroxy hydrocarbons, non-ionic PEG-7
hydrogenated castor oil (Cremophore WO7®), polyglyceryl-4 isostearate and cetyl dimethicone copolyol and hexyl laurate (Abil WE09), PEG-30 dipolyhydroxystearate (Arlacel P 135®), sorbitan sesquioleate, polyglyceryl-3- diisostearate, polyclyceryl-3-oleate, and polyglyceryl-4-isostearate.
9. The composition of claim 4 further comprising a co-emulsifier.
10. The composition of claim 9 wherein the co-emulsifer is methyl glucose isostearate.
11. The composition of claim 1 wherein the lipids comprise at least one of cholesterol esters, ceramide, triglycerides, cholesterol, free fatty acids, phospholipids, wax esters, squalene, wax diesters, or cholesterol sulfate.
12. The composition of claim 4 wherein the emulsifying agent is at least one of PEG-30 dipolyhydroxystearate (Arlacel P 135®) or sorbitan sesquioleate.
13. The composition of claim 1 wherein the water phase retains greater than about 65%w/w water of the total composition.
14. A synthetic vernix composition comprising hydratable emulsified particles dispersed in a continuous lipid phase wherein the lipid is selected from at least one of lanolin, squalene, linoleic acid, cholesterol, ceramide, wax, triglyceride, at least one emulsifying agent selected from sorbitan sesquioleate or PEG30 dipolyhydroxystearate, the hydratable emulsified particles capable of retaining at least 65%^ water .
15. The composition of claim 14 comprising about 1.5%** to about 2%^ lanolin, about 3.2%™* to about 5.8%^ squalene, about 0.8%^ to about 1.5%^ linoleic acid, about 4%wt to about 6%^ cholesterol, about 0.7%^ to about
1.5%wt ceramide III, about 3%^ to about 4.2%* beeswax, about 1 %w to about 2%wt capric/caprilic triglyceride, about 1.5%^ PEG30 dipolyhydroxystearate, and about 0.5%^ sorbitan sesquioleate.
16. The composition of claim 14 comprising about 2% ^ lanolin, about 3.5% ** squalene, about 0.8% wt linoleic acid, about 6% ** cholesterol, about 1.5% ^ ceramide III, about 4.2% ^ beeswax, about 1 % ^ capric caprilic triglyceride, about 1.5% ^ PEG30 dipolyhydroxystearate, about 0.5% wt sorbitan sesquioleate, and about 1 % ^ cholesterol sulfate.
17. The composition of claim 15 further comprising about 0% to about 3% cholesterol sulfate.
18. The composition of claim 15 further comprising about 0%^ to about 5%^ mineral oil.
19. The composition of claim 14 comprising about 2% ^ lanolin, about 4% ^ squalene, about 1 % ^ linoleic acid, about 5% ^ mineral oil, about 4% ^ cholesterol, about 1 % ** ceramide III, about 3% "* beeswax, about 2% "* capric caprilic triglyceride, about 1.5%^ PEG30 dipolyhydroxystearate, and about 0.5% ^ sorbitan sesquioleate.
20. The composition of claim 14 comprising about 2% wt lanolin, about 4% ^ squalene, about 1% ^ linoleic acid, about 3.5% ** mineral oil, about 5.5% "* cholesterol, about 1 % ^ ceramide III, about 3% "" beeswax, about 2% ^ capric caprilic triglyceride, about 1.5% ^ PEG30 dipolyhydroxystearate, and about 0.5% ^ sorbitan sesquioleate.
21. The composition of claim 14 comprising about 2% ^ lanolin, about 4% ^ squalene, about 1% ^ linoleic acid, about 3% ^ mineral oil, about 5.5% *" cholesterol, about 1% "" ceramide III, about 4.2% ^ beeswax, about
1.5% ^ capric caprilic triglyceride, about 1.5% ^ PEG30 dipolyhydroxystearate, and about 0.5%^ sorbitan sesquioleate.
22. The composition of claim 14 wherein the water phase further comprises magnesium sulfate, glycerin, and at least one of methylparaben or propylparaben.
23. The composition of claim 22 comprising about 0.5%wt magnesium sulfate and about 2.5%^ to about 5%^ glycerin.
24. A synthetic vernix composition comprising hydratable emulsified particles dispersed in a continuous lipid phase wherein the lipid is selected from at least one of lanolin, stearyl alcohol, wax, mineral oil, or petrolatum; at least one emulsifying agent selected from cetyl dimethicone copolyol or polyglyceryl-4-isostearate and cetyl dimethicone copolyol and hexyl laurate (Abil WE 09), the hydratable emulsified particles capable of retaining at least 65%^ water.
26. The composition of claim 24 comprising about 2.7%^ lanolin, about 3.5%wt stearyl alcohol, about 1.7%^ wax, about 6.4%^ mineral oil, about 5%^ petrolatum, about 20Z0^ AbH WE 09, and about 1 %* cetyl dimethicone copolyol.
27. The composition of claim 24 wherein the water phase further comprises glycerin, sodium chloride, and methylparaben.
28. A method of treating a skin surface of an individual to remove a soiling material from the soiled skin surface, the method comprising applying a synthetic vernix composition to the soiled skin surface in an effective amount for removal of the soiling material, and thereafter removing the composition and soiling material from the skin surface, the synthetic vernix composition comprising a continuous lipid phase consisting essentially of physiologic lipids, and a hydratable water phase of simulated cells dispersed in the lipid phase, the hydratable water phase capable of retaining greater than about 65%w/w water of the total composition, said composition in a hydrated film form having a water vapor transmission rate that is between about 85% of the transmission rate through a substantially highly permeable film and about 5% of the transmission rate through a substantially highly occlusive film by a modified ASTM E96E procedure B, and having up to about 38% evaporative water loss from 0 h to 0.5 hr, and up to about 8% evaporative water loss from 0.5 hr to 3 hr.
29. The method of claim 28 wherein the simulated cells are water- in-oil emulsified particles.
30. A method of cleansing a soiled skin surface, the method comprising providing to the soiled skin surface a synthetic vernix composition simulating native vernix, the synthetic vernix composition comprising hydratable emulsified particles dispersed in a continuous lipid phase wherein the lipid is selected from at least one of lanolin, squalene, linoleic acid, cholesterol, ceramide III, wax, or triglyceride; and at least one emulsifying agent selected from sorbitan sesquioleate or PEG30 dipolyhydroxystearate, the hydratable emulsified particles capable of retaining at least 65%^ water.
31. The method of claim 30 wherein the composition comprises about 1.5%** to about 2%^ lanolin, about 3.2%** to about 5.8%^ squalene, about 0.8%^ to about 1.5%wt linoleic acid, about 4%^ to about 6%^ cholesterol, about 0.7%^ to about 1.5%*" ceramide III, about 3%^ to about 4.2%wt beeswax, about 10Zo^ to about 2%^ capric/caprilic triglyceride, about 1.5%wt PEG30 dipolyhydroxystearate, and about 0.5%*" sorbitan sesquioleate.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002595023A CA2595023A1 (en) | 2005-01-19 | 2005-01-19 | Simulated vernix compositions for skin cleansing and other applications |
EP05711722A EP1838274A1 (en) | 2005-01-19 | 2005-01-19 | Simulated vernix compositions for skin cleansing and other applications |
JP2007552100A JP2008527036A (en) | 2005-01-19 | 2005-01-19 | Simulated vernix composition for skin cleansing and other applications |
PCT/US2005/001839 WO2006078245A1 (en) | 2005-01-19 | 2005-01-19 | Simulated vernix compositions for skin cleansing and other applications |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2005/001839 WO2006078245A1 (en) | 2005-01-19 | 2005-01-19 | Simulated vernix compositions for skin cleansing and other applications |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006078245A1 true WO2006078245A1 (en) | 2006-07-27 |
Family
ID=34960419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/001839 WO2006078245A1 (en) | 2005-01-19 | 2005-01-19 | Simulated vernix compositions for skin cleansing and other applications |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1838274A1 (en) |
JP (1) | JP2008527036A (en) |
CA (1) | CA2595023A1 (en) |
WO (1) | WO2006078245A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009146852A1 (en) * | 2008-06-02 | 2009-12-10 | Universiteit Leiden | A topical composition comprising the isolated non-polar lipid fraction of lan0lin4 |
US7959935B2 (en) | 2002-05-03 | 2011-06-14 | Children's Hospital Medical Center | Simulated vernix compositions for skin cleansing and other applications |
US11890294B2 (en) | 2017-05-10 | 2024-02-06 | Hyphens Pharma Pte. Ltd. | Skin barrier composition |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105030616B (en) * | 2015-08-21 | 2017-11-21 | 北京太和逸肤科技有限公司 | The bionical vernix caseosa skin care compositions of external application, preparation and preparation method thereof |
JP6954623B2 (en) * | 2018-01-22 | 2021-10-27 | 株式会社アンズコーポレーション | Emulsified cosmetics and manufacturing method of emulsified cosmetics |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3849548A (en) * | 1970-11-16 | 1974-11-19 | Colgate Palmolive Co | Cosmetic compositions |
US5631012A (en) * | 1994-09-02 | 1997-05-20 | Shanni; David | Cosmetic preparations for moisturizing human skin containing specific lipids |
US5989577A (en) * | 1998-03-02 | 1999-11-23 | Children's Hospital Medical Center | Nontoxic vernix compositions and method of producing |
US6333041B1 (en) * | 1998-03-02 | 2001-12-25 | Children's Hospital Medical Center | Nontoxic vernix compositions and method of producing |
WO2002047642A1 (en) * | 2000-12-15 | 2002-06-20 | Schering Ag | Hypoallergenic and non-irritant skin care formulations |
WO2002100373A1 (en) * | 2001-06-13 | 2002-12-19 | Knut Haadem Ab | Skin preparation |
WO2003092646A1 (en) * | 2002-05-03 | 2003-11-13 | Children's Hospital Medical Center | Simulated vernix compositions for skin cleansing and other applications |
EP1555017A1 (en) * | 2004-01-19 | 2005-07-20 | Beiersdorf AG | Low-viscosity W/O Emulsions |
-
2005
- 2005-01-19 WO PCT/US2005/001839 patent/WO2006078245A1/en active Application Filing
- 2005-01-19 EP EP05711722A patent/EP1838274A1/en not_active Withdrawn
- 2005-01-19 JP JP2007552100A patent/JP2008527036A/en not_active Withdrawn
- 2005-01-19 CA CA002595023A patent/CA2595023A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3849548A (en) * | 1970-11-16 | 1974-11-19 | Colgate Palmolive Co | Cosmetic compositions |
US5631012A (en) * | 1994-09-02 | 1997-05-20 | Shanni; David | Cosmetic preparations for moisturizing human skin containing specific lipids |
US5989577A (en) * | 1998-03-02 | 1999-11-23 | Children's Hospital Medical Center | Nontoxic vernix compositions and method of producing |
US6333041B1 (en) * | 1998-03-02 | 2001-12-25 | Children's Hospital Medical Center | Nontoxic vernix compositions and method of producing |
WO2002047642A1 (en) * | 2000-12-15 | 2002-06-20 | Schering Ag | Hypoallergenic and non-irritant skin care formulations |
WO2002100373A1 (en) * | 2001-06-13 | 2002-12-19 | Knut Haadem Ab | Skin preparation |
WO2003092646A1 (en) * | 2002-05-03 | 2003-11-13 | Children's Hospital Medical Center | Simulated vernix compositions for skin cleansing and other applications |
EP1555017A1 (en) * | 2004-01-19 | 2005-07-20 | Beiersdorf AG | Low-viscosity W/O Emulsions |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7959935B2 (en) | 2002-05-03 | 2011-06-14 | Children's Hospital Medical Center | Simulated vernix compositions for skin cleansing and other applications |
WO2009146852A1 (en) * | 2008-06-02 | 2009-12-10 | Universiteit Leiden | A topical composition comprising the isolated non-polar lipid fraction of lan0lin4 |
US11890294B2 (en) | 2017-05-10 | 2024-02-06 | Hyphens Pharma Pte. Ltd. | Skin barrier composition |
Also Published As
Publication number | Publication date |
---|---|
EP1838274A1 (en) | 2007-10-03 |
CA2595023A1 (en) | 2006-07-27 |
JP2008527036A (en) | 2008-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7959935B2 (en) | Simulated vernix compositions for skin cleansing and other applications | |
DE69927288T2 (en) | Adsorbent composition and its use for binding skin irritating agents. | |
US7807188B2 (en) | Simulated vernix compositions for skin cleansing and other applications | |
AU768087B2 (en) | Skin-friendly absorbent articles and compositions | |
KR100848753B1 (en) | Absorbent articles with non-aqueous compositions containing anionic polymers | |
US6534074B2 (en) | Absorbent articles providing skin health benefits | |
US6749860B2 (en) | Absorbent articles with non-aqueous compositions containing botanicals | |
US6503526B1 (en) | Absorbent articles enhancing skin barrier function | |
JP2003510132A (en) | Articles having mobile breathable skin care compositions | |
JP2001515760A (en) | Methods for maintaining or improving skin health | |
CZ2000850A3 (en) | Method for improving state of skin | |
CN103957867A (en) | Medicinal skin protection composition with an active ingredient combination which improves the skin barrier | |
EP1838274A1 (en) | Simulated vernix compositions for skin cleansing and other applications | |
US5989577A (en) | Nontoxic vernix compositions and method of producing | |
Elsner | What textile engineers should know about the human skin | |
US6562358B2 (en) | Nontoxic vernix compositions and method of producing | |
Tansirikongkol | Development of a synthetic vernix equivalent, and its water handling and barrier protective properties in comparison with vernix caseosa | |
Visscher | Environmental interactions | |
MXPA01010758A (en) | Skin-friendly absorbent articles and compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2595023 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005711722 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007552100 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005711722 Country of ref document: EP |